Malignancy and vasculitis

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Citation | vasculitis  | Malignancy |  N | results |
| Risk of vasculitis in malignancies |
| Dar 2021 | giant cell arteritis (GCA) age 50+ yrs | Hematologic cancers | 7213 GCA pts 32,987 controls. | hematologic cancers before GCA Dx1.9% Malignancy afterGCA Dx2.0%[See Table 1 below](#Dar) for complete list |
| Robak 2021 | Vasculitis syndromes | Hairy cell leukemia (HCL) | review | Vasculitis reported in 4.5–8% of cases with lymphoid malignancies |
| Fain 2007 | cutaneous leukocytoclastic (45%), polyarteritis nodosa (36.7%), Wegener's granulomatosis (6.7%), microscopic polyangiitis (5%), and Henoch-Schönlein purpura (5% | lymphoid | 557 new patients with vasculitis | vasculitides associated with malignancies represented 5.2% of the vasculitides registered (n=60)hematologic: 63.1%CLL: 4 (6.2%) |
| Jachiet 2018 | systemic vasculitis | lymphoma | 2503 patients lymphoma | Among 2503 patients with lymphoma, 108 (4.3%) had autoimmune manifestations (AIMs), of which 5.6% were systemic vasculitis  |
| Hamidou 2000 | ANCA and vasculitis | Hematologic malignancies | 200,(60 myelodysplastic syndrome (MDS), 140 lymphoind malignancies group 2) age 36-96 y | N= 6 of the 200 pts, were ANCA positive 1 of which was CLLof the other 194 12 had vasculitis of those 35 CLL pts 1 systemic vasculitis, 1 relapsing poluchondritis |

Table 1Malignancy rates by site, relative to the time of GCA diagnosis, or enrollment time for controls. from Dar 2021

|  |  |
| --- | --- |
| Cancer Site | GCA pts |
| Hematologic cancers | 274 (3.8%) |
| Before diagnosis/enrollment | 137 (1.9%) |
| After diagnosis/enrollment | 144 (2.0%) |
| Acute Leukemia | 36 (0.5%) |
| Before diagnosis/enrollment | 16 (0.2%) |
| After diagnosis/enrollment | 20 (0.3%) |
| Chronic Leukemia | 55 (0.8%) |
| Before diagnosis/enrollment | 21 (0.3%) |
| After diagnosis/enrollment | 32 (0.4%) |
| Myelodysplastic syndrome | 26 (0.4%) |
| Before diagnosis/enrollment | 14 (0.2%) |
| After diagnosis/enrollment | 12 (0.2%) |
| Multiple Myeloma | 71 (1%) |
| Before diagnosis/enrollment | 29 (0.4%) |
| After diagnosis/enrollment | 39 (0.5%) |
| Non-Hodgkin Lymphoma | 121 (1.7%) |
| Before diagnosis/enrollment | 68 (0.9%) |
| After diagnosis/enrollment | 52 (0.7%) |
| Hodgkin Lymphoma | 32 (0.4%) |
| Before diagnosis/enrollment | 21 (0.3%) |
| After diagnosis/enrollment | 11 (0.2%) |

References

Dar, L., N. Ben-Shabat, S. Tiosano, . . . H. Amital (2021). "The Incidence and Predictors of Solid- and Hematological Malignancies in Patients with Giant Cell Arteritis: A Large Real-World Database Study." Int J Environ Res Public Health **18**(14). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306706/>

Robak, E., D. Jesionek-Kupnicka and T. Robak (2021). "Skin changes in hairy cell leukemia." Ann Hematol **100**(3): 615-625. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914191/>

Fain, O., M. Hamidou, P. Cacoub, . . . L. Guillevin (2007). "Vasculitides associated with malignancies: analysis of sixty patients." Arthritis Rheum **57**(8): 1473-1480. <https://onlinelibrary.wiley.com/doi/10.1002/art.23085>

Jachiet, V., A. Mekinian, F. Carrat, . . . O. Fain (2018). "Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study." Leuk Lymphoma **59**(6): 1399-1405. [https://jnj.sharepoint.com/:b:/r/teams/epi/Shared%20Documents/References/Oncology/Jachiet%202018.pdf?csf=1&web=1&e=1rqbOX](https://jnj.sharepoint.com/%3Ab%3A/r/teams/epi/Shared%20Documents/References/Oncology/Jachiet%202018.pdf?csf=1&web=1&e=1rqbOX)

Hamidou, M. A., S. Derenne, M. A. Audrain, . . . J. Y. Grolleau (2000). "Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study." Rheumatology (Oxford) **39**(4): 417-420. [https://jnj.sharepoint.com/:b:/r/teams/epi/Shared%20Documents/References/Oncology/Hamidou%202000.pdf?csf=1&web=1&e=qZbHPL](https://jnj.sharepoint.com/%3Ab%3A/r/teams/epi/Shared%20Documents/References/Oncology/Hamidou%202000.pdf?csf=1&web=1&e=qZbHPL)